Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Ponders Drug Pricing In Opioid Abuse Analysis

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency, of course, cannot consider drug pricing in approval decisions, but is making itself aware as it mulls broader policy changes.

Advertisement

Related Content

FDA’s Naloxone Product Approval Standards May See Changes
Naloxone Costs Could Temper Non-Rx Access Even As Distribution Spreads

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register